natgillin/translations-raw huggingface dataset:
Kalydeco tablets are indicated for the treatment of patients with cystic fibrosis (CF) aged 6 years and older and weighing 25 kg or more who have one of the following gating (class III) mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R (see sections 4.4 and 5.1).
Kalydeco tablete indicirane su za liječenje bolesnika s cističnom fibrozom (CF) u dobi od 6 i više godina i tjelesne težine od 25 kg ili više, koji u genu CFTR imaju jednu od sljedećih mutacija (III. klase) zbog koje dolazi do nepravilne regulacije kanala: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N ili S549R (vidjeti dijelove 4.4 i 5.1).
Kalydeco tablets are indicated for the treatment of patients with cystic fibrosis (CF) aged 6 years and older and weighing 25 kg or more who have one of the following gating mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R.
Kalydeco tablete namijenjene su liječenju bolesnika s cističnom fibrozom (CF) u dobi od 6 i više godina i tjelesne težine od 25 kg ili više, koji u genu CFTR imaju jednu od sljedećih mutacija zbog koje dolazi do nepravilne regulacije kanala: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N ili S549R.
Kalydeco tablets are not adequate for children under 6 years of age.
Tablete lijeka Kalydeco nisu pogodne za djecu mlađu od 6 godina.
Kalydeco was also effective in patients with mutations other than G551D.
Kalydeco je također bio djelotvoran u bolesnika s drugim mutacijama uz mutaciju G551D.
Kalydeco was compared with placebo in two main studies involving 219 patients with cystic fibrosis who had the G551D mutation.
Kalydeco je uspoređen s placebom u dva glavna ispitivanja koja su obuhvatila 219 bolesnika s cističnom fibrozom s mutacijom G551D.
Kalydeco was shown to be effective at improving lung function in patients with cystic fibrosis who had the G551D mutation.
Utvrđeno je kako je Kalydeco djelotvoran u poboljšavanju funkcije pluća u bolesnika s cističnom fibrozom koji imaju mutaciju G551D.
KANUMA 2 mg/ml concentrate for solution for infusion sebelipase alfa
KANUMA 2 mg/ml koncentrat za otopinu za infuziju sebelipase alfa
KANUMA contains sodium
KANUMA sadrži natrij
KANUMA has to be diluted with sodium chloride 9 mg/ml (0.9%) solution for infusion using aseptic technique.
KANUMA se mora razrijediti otopinom natrijevog klorida za infuziju od 9 mg/ml (0,9%) uz korištenje aseptične tehnike.
KANUMA is for intravenous use only.
KANUMA je namijenjena samo za intravensku primjenu.
KANUMA is supplied as a concentrate for solution for infusion.
KANUMA je dostupna kao koncentrat za otopinu za infuziju.
KANUMA should be prepared and used according to the following steps.
KANUMU treba pripremiti i primijeniti prema sljedećim uputama.
Kaplan Meier estimates of the median duration of event-free survival were 35 months in the R-CHOP arm compared to 13 months in the CHOP arm, representing a risk reduction of 41 %.
Prema Kaplan-Meierovoj procjeni, medijan preživljenja bez događaja iznosio je 35 mjeseci za R-CHOP skupinu, odnosno 13 mjeseci za CHOP skupinu, što predstavlja smanjenje rizika za 41%.
Kaplan Meier plot of PFS
Kaplan Meierov prikaz PFS-a
Kaplan- Meier curves of investigator assessed overall survival (post-hoc analysis 20 May 2013) is presented in Figure 3.
Kaplan-Meierove krivulje ukupnog preživljenja prema ocjeni ispitivača (post-hoc analiza, 20. svibnja 2013.) prikazane su na slici 3.
Kaplan--Meier Estimate of Median Time to Event (Months)
Kaplan-Meierova procjena medijana vremena do pojave događaja (mjeseci)
Kaplan-Meier analysis of time to augmentation showed no significant difference between pramipexole and placebo groups.
Kaplan- Meierova analiza vremena do pojave augmentacije nije pokazala značajnu razliku između skupina na pramipeksolu i placebu.
Kaplan-Meier analysis showed shorter time to treatment failure in patients treated with gliclazide, compared with pioglitazone.
Kaplan- Meierovom analizom pokazalo se da je vrijeme do prestanka odgovora na terapiju u bolesnika liječenih gliklazidom kraće nego kod liječenja pioglitazonom.
Kaplan-Meier Curve of Time to Persistent 10% 6MWD Worsening
Kaplan-Meierova krivulja vremena do trajnog 10% pogoršanja udaljenosti prijeđene u 6 minuta
Kaplan-Meier curves OS by treatment arm in randomised Phase 3 Study 1014 (full analysis population) in patients with previously untreated ALK-positive advanced NSCLC
Kaplan-Meierove krivulje za ukupno preživljenje po liječenoj skupini u randomiziranom Ispitivanju 1014 faze 3 (potpuna analiza populacije) u bolesnika s prethodno neliječenim ALK-pozitivnim uznapredovalim NSCLC-om
Kaplan-Meier estimate, months a
Kaplan-Meier procjena, mjeseci a
Kaplan-Meier medians Afinitor : 11.04 months Placebo : 4.60 months
Kaplan-Meierovi medijani Afinitor : 11,04 mjeseci Placebo : 4,60 mjeseci
Kaplan-Meier medians Everolimus: 4.90 months
Kaplan-Meierovi medijani Everolimus: 4,90 mjeseci
Kaplan-Meier plots of time to first on-study SRE
Kaplan-Meierove krivulje vremena do prvog SRE tijekom ispitivanja
Kaplan-Meier relapse rates at week 16 were 35% for aripiprazole and 52% for placebo; the hazard ratio for relapse within 16 weeks (aripiprazole/placebo) was 0.57 (non-statistically significant difference).
Kaplan-Meierova stopa relapsa u 16. tjednu za bolesnike na aripiprazolu iznosila je 35 % dok je za one na placebu bila 52 %; omjer hazarda relapsa u tih 16 tjedana (aripiprazol/placebo) bio je 0,57 (nije statistički značajna razlika).
Kaplan‐Meier Estimate of Median Time to Event (Months)
Kaplan-Meierova procjena medijana vremena do pojave događaja (mjeseci)
Karnofsky Index, a measure of your general performance status.
Karnofsky indeks, koji predstavlja procjenu Vašeg općeg funkcionalnog stanja.
Karvea 150 mg film-coated tablets are supplied in blister packs of 14, 28, 30, 56, 84, 90 or 98 film- coated tablets.
Karvea 150 mg filmom obložene tablete dostupne su u blister pakiranjima s 14, 28, 30, 56, 84 i 98 filmom obloženih tableta.
Karvea 150 mg film-coated tablets are white to off-white, biconvex, and oval-shaped with a heart debossed on one side and the number 2872 engraved on the other side.
Karvea 150 mg filmom obložene tablete su bijele do gotovo bijele, bikonveksne i ovalne, s utisnutom oznakom srca na jednoj i brojem 2872 na drugoj strani.
Karvea 150 mg film-coated tablets.
Karvea 150 mg filmom obložene tablete
Karvea 150 mg tablets are white to off-white, biconvex, and oval-shaped with a heart debossed on one side and the number 2772 engraved on the other side.
Karvea 150 mg tablete su bijele do gotovo bijele, bikonveksne i ovalne, s utisnutom oznakom srca na jednoj i brojem 2772 na drugoj strani.
Karvea 150 mg tablets irbesartan
Karvea 150 mg tablete irbesartan
Karvea 150 mg tablets.
Karvea 150 mg tablete
Karvea 300 mg film-coated tablets are supplied in blister packs of 14, 28, 30, 56, 84, 90 or 98 film- coated tablets.
Karvea 300 mg filmom obložene tablete dostupne su u blister pakiranjima s 14, 28, 30, 56, 84 i 98 filmom obloženih tableta.
Karvea 300 mg film-coated tablets are white to off-white, biconvex, and oval-shaped with a heart debossed on one side and the number 2873 engraved on the other side.
Karvea 300 mg filmom obložene tablete su bijele do gotovo bijele, bikonveksne i ovalne, s utisnutom oznakom srca na jednoj i brojem 2873 na drugoj strani.
Karvea 300 mg film-coated tablets.
Karvea 300 mg filmom obložene tablete
Karvea 300 mg tablets are white to off-white, biconvex, and oval-shaped with a heart debossed on one side and the number 2773 engraved on the other side.
Karvea 300 mg tablete su bijele do gotovo bijele, bikonveksne i ovalne, s utisnutom oznakom srca na jednoj i brojem 2773 na drugoj strani.
Karvea 300 mg tablets irbesartan
Karvea 300 mg tablete irbesartan
Karvea 300 mg tablets.
Karvea 300 mg tablete
Karvea 75 mg film-coated tablets are supplied in blister packs of 14, 28, 30, 56, 84, 90 or 98 film- coated tablets.
Karvea 75 mg filmom obložene tablete dostupne su u blister pakiranjima s 14, 28, 30, 56, 84, 90 ili 98 filmom obloženih tableta.
Karvea 75 mg film-coated tablets are white to off-white, biconvex, and oval-shaped with a heart debossed on one side and the number 2871 engraved on the other side.
Karvea 75 mg filmom obložene tablete su bijele do gotovo bijele, bikonveksne i ovalne, s utisnutom oznakom srca na jednoj i brojem 2871 na drugoj strani.
Karvea 75 mg film-coated tablets.
Karvea 75 mg filmom obložene tablete
Karvea 75 mg tablets are white to off-white, biconvex, and oval-shaped with a heart debossed on one side and the number 2771 engraved on the other side.
Karvea 75 mg tablete su bijele do gotovo bijele, bikonveksne i ovalne, s utisnutom oznakom srca na jednoj i brojem 2771 na drugoj strani.
Karvea 75 mg tablets irbesartan
Karvea 75 mg tablete irbesartan
Karvea 75 mg tablets.
Karvea 75 mg tablete
Karvea can be taken with or without food.
Karvea se može uzeti s hranom ili bez nje.
Karvea in combination with aliskiren- containing medicines (used to treat essential hypertension) must not be used in patients with diabetes, or moderate or severe kidney impairment.
U kombinaciji s lijekovima koji sadrže aliskiren (koristi se za liječenje esencijalne hipertenzije) Karvea se ne smije koristiti u bolesnika s dijabetesom, ili umjerenim do ozbiljnim oštećenjem funkcije bubrega.
Karvea is used in adult patients
Karvea se primjenjuje u odraslih bolesnika za
Karvea with food and drink
Karvea s hranom i pićem
Karvezide 150 mg/12.5 mg film-coated tablets are peach, biconvex, oval-shaped, with a heart debossed on one side and the number 2875 engraved on the other side.
Karvezide 150 mg/12,5 mg filmom obložene tablete su bikonveksne, ovalne tablete boje breskve s utisnutom oznakom srca na jednoj i brojem 2875 na drugoj strani.
Karvezide 150 mg/12.5 mg film-coated tablets.
Karvezide 150 mg/12,5 mg filmom obložene tablete
Karvezide 150 mg/12.5 mg may be administered in patients whose blood pressure is not adequately controlled with hydrochlorothiazide or irbesartan 150 mg alone;
Karvezide 150 mg/12,5 mg može se propisati bolesnicima čiji se krvni tlak ne može na odgovarajući način kontrolirati samo hidroklorotiazidom ili irbesartanom u dozi od 150 mg;
Karvezide 150 mg/12.5 mg tablets are peach, biconvex, oval-shaped, with a heart debossed on one side and the number 2775 engraved on the other side.
Karvezide 150 mg/12,5 mg tablete su bikonveksne, ovalne tablete boje breskve s utisnutom oznakom srca na jednoj i brojem 2775 na drugoj strani.
Karvezide 150 mg/12.5 mg tablets.
Karvezide 150 mg/12,5 mg tablete
Karvezide 300 mg/12.5 mg film-coated tablets are peach, biconvex, oval-shaped, with a heart debossed on one side and the number 2876 engraved on the other side.
Karvezide 300 mg/12,5 mg filmom obložene tablete su bikonveksne, ovalne tablete boje breskve s utisnutom oznakom srca na jednoj i brojem 2876 na drugoj strani.
Karvezide 300 mg/12.5 mg film-coated tablets.
Karvezide 300 mg/12,5 mg filmom obložene tablete
Karvezide 300 mg/12.5 mg may be administered in patients insufficiently controlled by irbesartan 300 mg or by Karvezide 150 mg/12.5 mg.
Karvezide 300 mg/12,5 mg može se propisati bolesnicima čiji se krvni tlak ne može na odgovarajući način kontrolirati irbesartanom u dozi od 300 mg ili lijekom Karvezide 150 mg/12,5 mg.
Karvezide 300 mg/12.5 mg tablets are peach, biconvex, oval-shaped, with a heart debossed on one side and the number 2776 engraved on the other side.
Karvezide 300 mg/12,5 mg tablete su bikonveksne, ovalne tablete boje breskve s utisnutom oznakom srca na jednoj i brojem 2776 na drugoj strani.
Karvezide 300 mg/12.5 mg tablets irbesartan/hydrochlorothiazide
Karvezide 300 mg/12,5 mg tablete irbesartan/hidroklorotiazid
Karvezide 300 mg/12.5 mg tablets.
Karvezide 300 mg/12,5 mg tablete
Karvezide 300 mg/25 mg film-coated tablets are pink, biconvex, oval-shaped, with a heart debossed on one side and the number 2788 engraved on the other side.
Karvezide 300 mg/25 mg filmom obložene tablete su bikonveksne, ovalne tablete boje breskve s utisnutom oznakom srca na jednoj i brojem 2788 na drugoj strani.
Karvezide 300 mg/25 mg film-coated tablets.
Karvezide 300 mg/25 mg filmom obložene tablete
Karvezide 300 mg/25 mg may be administered in patients insufficiently controlled by Karvezide 300 mg/12.5 mg.
Karvezide 300 mg/25 mg može se propisati bolesnicima čiji se krvni tlak ne može na odgovarajući način kontrolirati lijekom Karvezide 300 mg/12,5 mg.
Karvezide 300 mg/25 mg tablets irbesartan/hydrochlorothiazide
Karvezide 300 mg/25 mg tablete irbesartan/hidroklorotiazid
Karvezide can be taken with or without food.
Karvezide se može uzeti s hranom ili bez nje.
Karvezide is a combination of an angiotensin-II receptor antagonist, irbesartan, and a thiazide diuretic, hydrochlorothiazide.
Karvezide je kombinacija irbesartana, antagonista receptora angiotenzina II i hidroklorotiazida, tiazidskog diuretika.
Karvezide is not recommended in early pregnancy, and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at that stage (see pregnancy section).
Karvezide se ne preporučuje uzimati u ranoj trudnoći, a ne smije se uzimati nakon trećeg mjeseca trudnoće jer može ozbiljno naškoditi Vašem djetetu primjenjujete li ga u tom razdoblju (vidjeti dio o trudnoći).
Karvezide should not be given to children and adolescents (under 18 years).
Karvezide se ne smije davati djeci i adolescentima (mlađima od 18 godina).
Karvezide with food and drink
Karvezide s hranom i pićem
Karyotype
Kariotip
Kawasaki disease (major signs of the illness are for instance: fever, skin rash, swollen lymph glands, inflammation and rash of the mucous membranes of the mouth and throat)
Kawasakijeva bolest (glavni znakovi bolesti su na primjer: vrućica, kožni osip, otečene limfne žlijezde, upala i osip sluznica usta i grla)
Kawasaki disease was reported in 5 of 36,150 vaccine recipients (<0.1 %) and 1 of 35,536 placebo recipients (<0.1 %) with a relative risk (RR) of 4.9 [95 % CI, 0.6 – 239.1] (not statistically significant).
Kawasakijeva bolest prijavljena je u 5 od 36 150 primatelja cjepiva (<0,1%) te u 1 od 35 536 primatelja placeba (<0,1%) s relativnim rizikom (RR) od 4,9 [95% CI, 0,6-239,1] (nije statistički značajno).
Kawasaki disease, an illness in children where the blood vessels (arteries) in the body become enlarged.
Kawasakijeva bolest, dječja bolest kod koje se proširuju krvne žile (arterije) u tijelu.
Kawasaki disease, which causes multiple inflammations of several organs in the body;
Kawasakijeve bolesti, koja uzrokuje višestruke upale nekoliko organa u tijelu;
Kawasaki disease.
Kawasakijeve bolesti.
Kawasaki disease.
Kawasakijevoj bolesti.
Kd = Kyprolis plus dexamethasone; Vd = bortezomib plus dexamethasone; OS = overall survival; mo = months; NE = Not Estimable; HR = hazard ratio; CI = confidence interval
Kd = Kyprolis i deksametazon; Vd = bortezomib i deksametazon; OS = sveukupno preživljenje; mj = mjeseci; NP* = nije procjenjivo; HR = omjer hazarda; CI = interval pouzdanosti
Kd = Kyprolis plus dexamethasone; Vd = bortezomib plus dexamethasone; PFS = progression-free survival; mo = months; HR = hazard ratio; CI = confidence interval;
Kd = Kyprolis i deksametazon; Vd = bortezomib i deksametazon; PFS = preživljenje bez progresije bolesti; mj = mjeseci; HR = omjer hazarda; CI = interval pouzdanosti.
Kd Arm (N = 464)
Kd skupina (N = 464)
keep
ačuvati
Keep a note of where you have injected each week
Bilježite svaki tjedan gdje ste injicirali.
Keep a record of your injection
Vodite bilješke o injekcijama
Keep and store the opened diluent bottle under aseptic conditions because it is needed for dilution of the concentrate.
Otvorenu bocu s otapalom pohranite u aseptičkim uvjetima jer je potrebna za razrjeđivanje koncentrata.
Keep any remaining unused syringes in their original carton, in the refrigerator.
Preostale neupotrijebljene štrcaljke ostavite u hladnjaku u originalnoj kutiji.
Keep any remaining unused syringes in their original carton, in the refrigerator.
Preostale štrcaljke ostavite u hladnjaku u originalnoj kutiji.
Keep application sites covered with clothing when coming into contact with breast-feeding women or nursing babies.
Držite mjesta primjene pokrivena odjećom kada dolazite u kontakt s dojiljama ili dojenčadi.
Keep away from heat, sparks, open flame or other source of ignition.
Držati dalje od vrućine, iskre, otvorene vatre i drugih izvora paljenja.
Keep away from heat, sparks, open flame or other sources of ignition.
Držati dalje od topline, iskre, otvorenog plamena ili druge vrste paljenja.
Keep away from heat, sparks, open flame or other sources of ignition.
Iskorištene pipete držati izvan dosega i pogleda djece.
Keep away from the freezer compartment.
Držati dalje od odjeljka za zamrzavanje.
Keep bottle tightly closed in order to protect from moisture.
Bočicu čuvati čvrsto zatvorenu radi zaštite od vlage.
Keep breathing in even after you have heard the inhaler “CLICK” to be sure you get the full dose.
Nastavite udisati i nakon što ste čuli “KLIK“ kako biste bili sigurni da ćete uzeti cijelu dozu.
Keep breathing in even after you have heard the inhaler “CLICK” to be sure you get the full dose.
Nastavite udisati i nakon što ste čuli „KLIK“ inhalatora kako biste bili sigurni da ćete uzeti cijelu dozu.
Keep children away from faeces, urine or the vomit of treated dogs.
Ne dopuštajte djeci kontakt s fekalijama, urinom ili povraćanim sadržajem liječenih pasa.
keep discard
ačuvati baciti
Keep Discard
Sačuvati Baciti
Keep enough pressure on the skin and press the button with your thumb.
Zadržite dovoljan pritisak na koži i pritisnite gumb palcem.
Keep EVARREST dry after opening.
Čuvajte EVARREST suhim nakon otvaranja.
Keep filled syringe in your hand and do not touch syringe tip.
Držite napunjenu štrcaljku u ruci i nemojte dodirivati vršak štrcaljke.
Keep GANFORT out of the sight and reach of children.
Ovaj lijek čuvajte izvan pogleda i dohvata djece.
Keep GANFORT single-dose out of the sight and reach of children.
Ovaj lijek čuvajte izvan pogleda i dohvata djece.
Keep holding the injection button in and slowly count to 5.
Držite gumb za injiciranje pritisnutim i polako brojite do 5.
Keep holding the pen firmly against your skin.
Nastavite držati brizgalicu čvrsto uz kožu.
Keep holding your thumb on the button and then slowly count to 5 to deliver the full dose of the medicine.
Nastavite držati palac na dugmetu i polako brojite do 5 kako biste primijenili cijelu dozu lijeka.
Keep in outer carton in order to protect from light.
Čuvati u vanjskom pakiranju radi zaštite od svjetlosti
Keep in the outer carton in order to protect from light
Čuvati u vanjskoj kutiji radi zaštite od svjetlosti
Keep in touch with your doctor, and do not stop taking Combivir without your doctor’s advice.
Ostanite u kontaktu s Vašim liječnikom i nemojte prestati uzimati Combivir bez prethodnog savjetovanja s liječnikom.
Keep in touch with your doctor, and do not stop taking Epivir without your doctor’s advice.
Budite u kontaktu sa svojim liječnikom i nemojte prestati uzimati Epivir ako Vam to nije savjetovao liječnik.
Keep in touch with your doctor, and do not stop taking Kivexa without your doctor’s advice.
Ostanite u kontaktu sa svojim liječnikom i nemojte prestati uzimati lijek Kivexa bez prethodnog savjetovanja s liječnikom.
Keep in touch with your doctor, and do not stop taking Lamivudine Teva Pharma B.V. without your doctor’s advice.
Budite u kontaktu sa svojim liječnikom i nemojte prestati uzimati Lamivudin Teva Pharma B.V. ako Vam to nije savjetovao liječnik.
Keep in touch with your doctor, and do not stop taking Lamivudine/Zidovudine Teva without your doctor’s advice.
Ostanite u kontaktu s Vašim liječnikom i nemojte prestati uzimati Lamivudin/Zidovudin Teva bez prethodnog savjetovanja s liječnikom.
Keep in touch with your doctor, and do not stop taking Trizivir without your doctor’s advice.
Ostanite u redovitom kontaktu sa svojim liječnikom i nemojte prestati uzimati Trizivir bez prethodnog savjetovanja s njim.
Keep in touch with your doctor, and do not stop taking Ziagen without your doctor’s advice.
Ostanite u kontaktu s liječnikom i nemojte prestati uzimati Ziagen bez prethodnog savjetovanja sa svojim liječnikom.
Keep in touch with your doctor, and do not stop taking Ziagen without your doctor’s advice.
Ostanite u kontaktu sa svojim liječnikom i nemojte prestati uzimati Ziagen bez prethodnog savjetovanja sa svojim liječnikom.
Keep injection sites covered with airtight and watertight dressings at all times.
Mjesta injiciranja držite pokrivena zavojem nepropusnim za zrak i vodu cijelo vrijeme.
Keep injection vial in the outer carton in order to protect from light.
Držati bočicu u vanjskom kartonu radi zaštite od svjetla.
Keep it safely
Čuvajte ga na sigurnom.
Keep it safely.
Čuvajte ga na sigurnom.
Keep it straight as you screw on.
Iglu držite ravno dok je navijate na brizgalicu.
keep keep
ačuvati sačuvati
Keep Mirvaso gel away from children.
Čuvajte Mirvaso gel dalje od djece.
Keep new pens in a fridge, at 2°C to 8°C.
Nove brizgalice čuvajte u hladnjaku, na temperaturi od 2°C do 8°C.
Keep out of reach and sight of children as accidental ingestion should be regarded as serious.
Čuvati izvan pogleda i dosega djece jer se slučajno gutanje treba smatrati ozbiljnim.
Keep out of the r sight and reach of children.
Čuvati izvan pogleda i dosega djece.
Keep out of the reach and sight of children
Čuvati izvan dohvata i pogleda djece
Keep out of the reach and sight of children
Čuvati izvan dohvata i pogleda djece.
Keep out of the reach and sight of children
Čuvati izvan dosega i pogleda djece.
Keep out of the reach and sight of children
Čuvati izvan pogleda i dohvata djece.
Keep out of the reach and sight of children.
Držati izvan pogleda i dosega djece.
Keep out of the reach and sight of children.
Lijek čuvajte izvan pogleda i dohvata djece.
Keep out of the reach and sight of children.
Ovaj lijek čuvajte izvan dohvata i pogleda djece.
Keep out of the reach and sight of children.
Ovaj lijek čuvajte izvan pogleda i dohvata djece.
Keep out of the reach and sight of children.
Čuvati izvan pogleda i dohvata djece
Keep out of the reach and sight of children.Accidental ingestion should be regarded as serious.
Slučajno gutanje treba smatrati ozbiljnim.
Keep out of the sight and raech of children.
Čuvati izvan pogleda i dohvata djece.
Keep out of the sight and reach and children.
Čuvati izvan pogleda i dohvata djece.
Keep out of the sight and reach and of children.
Čuvati izvan pogleda i dohvata djece.
Keep out of the sight and reach of children
Čuvati izvan dohvata i pogleda djece.
Keep out of the sight and reach of children
Čuvati izvan dosega i pogleda djece.
Keep out of the sight and reach of children and other household members.
Držite izvan pogleda i dosega djece ili drugih članova kućanstva.
Keep out of the sight and reach of children and other household members.
Ovaj lijek čuvajte izvan pogleda i dohvata djece ili drugih članova kućanstva.
Keep out of the sight and reach of children.
DRUGO(A) POSEBNO(A) UPOZORENJE(A), AKO JE POTREBNO
Keep out of the sight and reach of children.
Držati izvan pogleda i dosega djece
Keep out of the sight and reach of children.
Ovaj lijek čuvajte izvan pogleda i dohvata djece
Keep out of the sight and reach of children.
Ovo cjepivo čuvajte izvan pogleda i dohvata djece.
Keep out of the sight and reach of children.
Čuvati izvan dohvata i pogleda i djece.
Keep out of the sight and reach of children.
Čuvati izvan dohvata i pogleda i dohvata djece.
Keep out of the sight and reach of children.
Čuvati izvan izvan pogleda i dohvata djece
Keep out of the sight and reach of children.
Čuvati izvan pogelda i dohvata djece.
Keep out of the sight and reach of children.
Čuvati izvan pogleda dohvata djece.
Keep out of the sight and reach of children.
Čuvati izvan pogleda dosega djece.
Keep out of the sight and reach of children.
Čuvati izvan pogleda i dohvata.
Keep out of the sight and reach of children.
Čuvati izvan pogleda i pogleda djece.
Keep out of the sight and reach of children.
Čuvati izvan pogleda idohvata djece.
Keep out of the sight and reach of children.
Čuvati izvan pogledaa i dosega djece.
Keep out of the sight and reach of children.
Čuvati izvan pogledai dohvata djece.